Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

doi:10.1016/j.lungcan.2026.109302

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2026

Zhou Caicun, Tang Ke-Jing, Liu Baogang, Kim Sang-We, Kitazono Satoru, Ono Akira, Thiagarajan Muthukkumaran, Hung Jen-Yu, Boyer Michael, Çİl Timuçin, Yao Yu, Nagarkar Rajnish, Xie John, Bhattacharya Archan, Wortman-Vayn Honeylet, Baig Mahadi, Agrawal Trishala, Lorenzini Patricia, Lee Se-Hoon, Cho Byoung Chul

Abstract excerpt

BACKGROUND: Amivantamab is a bispecific, epidermal growth factor receptor (EGFR) and MET-proto-oncogene (MET)-targeting antibody with immune cell-directing activity. In the global Phase 3 PAPILLON trial, amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) significantly improved progression-free survival (PFS) vs chemotherapy alone in previously untreated participants with locally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Asia

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to Mutagenesis, Insertional

Share to Pemetrexed

Share to Proto-Oncogene Mas

Source

Open in PubMed

Identifiers

PMID: 41671628
DOI: 10.1016/j.lungcan.2026.109302

Genes

EGFR
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.PMID 41671628Read ↗

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Semantic proximity Read ↗

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.Semantic proximity Read ↗

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.Semantic proximity Read ↗

A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.Semantic proximity Read ↗

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.Semantic proximity Read ↗

Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Semantic proximity Read ↗

EGFR-Mutant NSCLC: Spotlight on Amivantamab.Semantic proximity Read ↗

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.